Ludovic Juen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1160120/publications.pdf

Version: 2024-02-01

1478505 1588992 8 121 8 6 citations h-index g-index papers 9 9 9 188 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Therapeutic Potential of MF-TTZ-MMAE, a Site-Specifically Conjugated Antibody-Drug Conjugate, for the Treatment of HER2-Overexpressing Breast Cancer. Bioconjugate Chemistry, 2022, 33, 418-426.	3.6	3
2	Inhibitors Targeting STAT5 Signaling in Myeloid Leukemias: New Tetrahydroquinoline Derivatives with Improved Antileukemic Potential. ChemMedChem, 2021, 16, 1034-1046.	3.2	4
3	Innovative Bioconjugation Technology for Antibody–Drug Conjugates: Proof of Concept in a CD30-Positive Lymphoma Mouse Model. Bioconjugate Chemistry, 2021, 32, 595-606.	3.6	13
4	Impact of Maleimide Disubstitution on Chemical and Biological Characteristics of HER2 Antibody–Drug Conjugates. ACS Omega, 2020, 5, 1557-1565.	3.5	10
5	Pharmacological Inhibition of Oncogenic STAT3 and STAT5 Signaling in Hematopoietic Cancers. Cancers, 2020, 12, 240.	3.7	49
6	A Novel Inhibitor of STAT5 Signaling Overcomes Chemotherapy Resistance in Myeloid Leukemia Cells. Cancers, 2019, 11, 2043.	3.7	15
7	New Inhibitor Targeting Signal Transducer and Activator of Transcription 5 (STAT5) Signaling in Myeloid Leukemias. Journal of Medicinal Chemistry, 2017, 60, 6119-6136.	6.4	17
8	Nonsymmetrical Azocarbonamide Carboxylates as Effective Mitsunobu Reagents. European Journal of Organic Chemistry, 2014, 2014, 7806-7809.	2.4	10